Department of Oncology, Aarhus University Hospital, Noerrebrogade, Aarhus, Denmark.
Radiother Oncol. 2010 Feb;94(2):173-80. doi: 10.1016/j.radonc.2010.01.001.
Brachytherapy in locally advanced cervical cancer is still widely based on 2D standard dose planning, although 3D image guidance is available. The purpose of this study was to compare point doses to 3D dose volume parameters for tumour and organs at risk (OARs), and to evaluate the improvement of dose parameters with MR image guided adaptive brachytherapy (IGABT).
MRI-based IGABT was performed in 72 consecutive patients. HR-CTV, IR-CTV, bladder, rectum and sigmoid were contoured according to GEC-ESTRO recommendations. BT standard dose planning was compared to MRI-based dose optimisation.
HR-CTV dose (D90) was highly variable in standard plans with point A dose prescription. In small tumours (<31 cc) HR-CTV was well covered by standard plans in 94% of patients, while OAR constraints were exceeded in 72% of patients. Optimisation decreased violation of OAR constraints to only 6% of patients while maintaining excellent target coverage. In large tumours (>31 cc) the dose optimisation improved the HR-CTV D90 by a mean of 7 Gy resulting in full coverage in 72% of patients as compared to 25% for standard plans, even while reducing violation of OAR constraints.
Point A dose is a poor surrogate of HR-CTV dose, and the use of 3D image-based dose planning is encouraged. MRI-based IGABT significantly improves target coverage and OAR dose.
尽管 3D 图像引导已经可用,但局部晚期宫颈癌的近距离治疗仍然广泛基于 2D 标准剂量规划。本研究的目的是比较肿瘤和危及器官(OAR)的点剂量与 3D 剂量体积参数,并评估 MR 图像引导自适应近距离治疗(IGABT)对剂量参数的改善。
对 72 例连续患者进行了基于 MRI 的 IGABT。根据 GEC-ESTRO 建议对 HR-CTV、IR-CTV、膀胱、直肠和乙状结肠进行了轮廓勾画。BT 标准剂量计划与 MRI 为基础的剂量优化进行了比较。
在标准计划中,点 A 剂量处方的 HR-CTV 剂量(D90)高度可变。在小肿瘤(<31 cc)中,标准计划能很好地覆盖 94%的患者的 HR-CTV,而 72%的患者的 OAR 限制被超过。优化将 OAR 限制的违反降低到仅 6%的患者,同时保持了良好的靶区覆盖。在大肿瘤(>31 cc)中,剂量优化使 HR-CTV D90 平均提高了 7 Gy,与标准计划的 25%相比,72%的患者实现了完全覆盖,即使同时减少了 OAR 限制的违反。
点 A 剂量是 HR-CTV 剂量的一个很差的替代物,鼓励使用 3D 图像为基础的剂量规划。基于 MRI 的 IGABT 显著改善了靶区覆盖和 OAR 剂量。